Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$94.95 -0.5%	$111.41	$76.53 ▼ $131.49	$22.79B	0.3	823,429 shs	624,359 shs
LNTH Lantheus	$96.16 -0.9%	$93.21	$58.16 ▼ $126.89	$6.59B	0.38	942,021 shs	617,660 shs
ONC Beigene	$267.39 +1.8%	$0.00	$126.97 ▼ $287.88	$26.38B	0.65	447,793 shs	514,626 shs
TEVA Teva Pharmaceutical Industries	$15.06 -2.8%	$17.21	$12.51 ▼ $22.80	$17.07B	0.82	9.65 million shs	7.84 million shs

Unlock the Potential in Options Trading

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.47%	-0.45%	-16.69%	-16.67%	+2.13%
LNTH Lantheus	-0.91%	-1.59%	+3.12%	+4.44%	+59.05%
ONC Beigene	+1.82%	+6.12%	+3.24%	+26,738,999,900.00%	+26,738,999,900.00%
TEVA Teva Pharmaceutical Industries	-3.02%	-6.92%	-10.33%	-33.88%	+4.26%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.403 of 5 stars	4.4	2.0	0.0	0.0	2.1	0.8	0.0
LNTH Lantheus	4.2597 of 5 stars	3.5	1.0	0.0	4.2	2.0	2.5	1.9
ONC Beigene	1.4657 of 5 stars	2.5	0.0	0.0	0.0	2.9	1.7	0.6
TEVA Teva Pharmaceutical Industries	2.5105 of 5 stars	3.4	3.0	0.8	0.0	2.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.89	Moderate Buy	$143.73	51.38% Upside
LNTH Lantheus	3.00	Buy	$129.43	34.60% Upside
ONC Beigene	3.00	Buy	$310.00	15.94% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	55.62% Upside

Current Analyst Ratings Breakdown

Latest LNTH, ONC, BNTX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $122.00
3/13/2025	ONC Beigene	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$259.00
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00
3/11/2025	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$171.44 ➝ $171.44
3/11/2025	BNTX BioNTech	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $143.00
3/6/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $20.00
3/3/2025	ONC Beigene	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$207.00 ➝ $320.00
2/28/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
2/28/2025	ONC Beigene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$348.00
2/28/2025	ONC Beigene	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$259.00 ➝ $313.00

(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	8.28	$4.08 per share	23.25	$92.17 per share	1.03
LNTH Lantheus	$1.53B	4.29	$8.03 per share	11.98	$11.91 per share	8.07
ONC Beigene	$3.81B	6.92	N/A	N/A	$37.10 per share	7.21
TEVA Teva Pharmaceutical Industries	$16.54B	1.03	$2.98 per share	5.05	$4.75 per share	3.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
LNTH Lantheus	$326.66M	$4.37	16.00	15.24	N/A	28.57%	44.29%	23.52%	5/1/2025 (Estimated)
ONC Beigene	-$881.71M	-$6.14	N/A	376.61	7.73	-25.94%	-25.12%	-14.95%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.72	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest LNTH, ONC, BNTX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/27/2025	Q4 2024	LNTH Lantheus	$1.57	$1.34	-$0.23	-$0.17	$376.61 million	$391.11 million
2/27/2025	Q4 2024	ONC Beigene	-$0.88	-$1.43	-$0.55	-$1.43	$1.09 billion	$1.13 billion
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.61%	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	6.72%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
LNTH Lantheus	N/A	1.65	1.56
ONC Beigene	0.05	1.93	1.72
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
LNTH Lantheus	99.06%
ONC Beigene	48.55%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
LNTH Lantheus	1.50%
ONC Beigene	7.43%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
LNTH Lantheus	700	68.48 million	68.48 million	Optionable
ONC Beigene	10,600	98.64 million	90.59 million	N/A
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

LNTH, ONC, BNTX, and TEVA Headlines

Recent News About These Companies

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now

March 28 at 6:11 AM | fool.com

Teva Pharmaceutical Industries (NYSE:TEVA) Rating Lowered to Hold at StockNews.com

March 28 at 3:09 AM | americanbankingnews.com

Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win

March 27 at 6:28 PM | msn.com

Teva to Host Conference Call to Discuss First [...]

March 27 at 6:28 PM | aktiencheck.de

Teva Pharmaceutical Industries Ltd: Teva Releases Q1 2025 Aide Memoire

March 27 at 6:28 PM | finanznachrichten.de

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27 at 4:45 PM | financialpost.com

Teva Releases Q1 2025 Aide Memoire

March 27 at 4:45 PM | financialpost.com

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27 at 4:30 PM | globenewswire.com

Teva Releases Q1 2025 Aide Memoire

March 27 at 4:30 PM | globenewswire.com

Drugmakers accused of a price-fixing scheme have agreed to a $49M settlement, state says

March 27 at 1:27 PM | yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded to "Hold" Rating by StockNews.com

March 27 at 2:05 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Sound Shore Management Inc. CT's 3rd Largest Position

March 25, 2025 | marketbeat.com

Emerald Advisers LLC Has $1.10 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 25, 2025 | marketbeat.com

KLP Kapitalforvaltning AS Takes $8.97 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 25, 2025 | marketbeat.com

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks

March 24, 2025 | fool.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Boston Partners

March 24, 2025 | marketbeat.com

Teacher Retirement System of Texas Raises Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 23, 2025 | marketbeat.com

Blueshift Asset Management LLC Cuts Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 22, 2025 | marketbeat.com

iA Global Asset Management Inc. Sells 85,772 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

March 22, 2025 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded at StockNews.com

March 22, 2025 | americanbankingnews.com

2TEVA : Teva Pharmaceutical Indus's Options: A Look at What the Big Money is...

March 21, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
5 Best Gold ETFs for March to Curb Recession Fears
By Jeffrey Neal Johnson | February 28, 2025
View 5 Best Gold ETFs for March to Curb Recession Fears
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
By Leo Miller | March 13, 2025
View 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
3 Semiconductor Stocks Flying Under the Radar—But Not for Long
By Nathan Reiff | March 20, 2025
View 3 Semiconductor Stocks Flying Under the Radar—But Not for Long
Boeing Stock Is Edging Out Airbus Again, Here’s How
By Jea Yu | March 4, 2025
View Boeing Stock Is Edging Out Airbus Again, Here’s How

LNTH, ONC, BNTX, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$94.95 -0.45 (-0.47%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$93.62 -1.33 (-1.40%)

As of 03/28/2025 07:37 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Lantheus NASDAQ:LNTH

$96.16 -0.88 (-0.91%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$94.58 -1.58 (-1.64%)

As of 03/28/2025 08:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Beigene NASDAQ:ONC

$267.39 +4.79 (+1.82%)

As of 03/28/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Teva Pharmaceutical Industries NYSE:TEVA

$15.06 -0.44 (-2.81%)

Closing price 03/28/2025 03:59 PM Eastern

Extended Trading

$15.07 +0.02 (+0.13%)

As of 03/28/2025 07:57 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time